rac-di-tert-butyl (1,2-trans)-cyclohex-4-ene-1,2-diyldicarbamate | 208533-46-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: rac-di-tert-butyl (1,2-trans)-cyclohex-4-ene-1,2-diyldicarbamate
• 英文别名: di-tert-butyl trans-cyclohex-4-ene-1,2-diyldicarbamate；rac-di-tert-butyl ((trans)-cyclohex-4-ene-1,2-diyl)dicarbamate；N,N'-[(1R)-4-Cyclohexene-1beta,2alpha-diyl]bis(carbamic acid tert-butyl) ester；tert-butyl N-[(1R,6R)-6-[(2-methylpropan-2-yl)oxycarbonylamino]cyclohex-3-en-1-yl]carbamate
• CAS: 208533-46-4
• 化学式: C₁₆H₂₈N₂O₄
• 分子量: 312.409
• InChiKey: IBBVWOZAKKWMOG-VXGBXAGGSA-N

物化性质

• 沸点：
  434.2±45.0 °C(Predicted)
• 密度：
  1.07±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  76.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  rac-di-tert-butyl (1,2-trans)-cyclohex-4-ene-1,2-diyldicarbamate 在 palladium on activated charcoal 超重氢 作用下， 以 乙酸乙酯 为溶剂， 反应 1.0h， 生成 [3H2]-(R,R)-1,2-bis(tert-butoxycarbamino)cyclohexane
  参考文献：
  名称：

  Synthesis of [3H2]-(R,R)-1,2-diaminocyclohexaneoxalatoplatinum(II), [3H2]-Oxaliplatin

  摘要：

  A synthesis of [H-3(2)]-(R, R)-1,2-diaminocyclohexaneoxalatoplatinum(II), [H-3(2)-Oxaliplatin, 2, is described. rac-trans-4-Cyclohexene-1,2-dicarboxylic acid diethyl ester, 6, was converted to rac-trans-1,2-diaminocyclohex-4-ene, 7, by modification of known chemistry aimed at avoiding reported hazards. Resolution of the diamine, 7, with L-(+)-tartaric acid afforded the (R,R)-1,2-diaminocyclohex-4-ene, 8, which was converted to the (R,R)-1,2-bis(tert-butoxycarbamino)cyclohex-4-ene, 10, and tritiated to yield [H-3(2)-(R,R)-1,2-bis(tert-butoxycarbamino)cyclohexane, 11. Hydrolysis of 11 afforded [H-3(2)]-(R,R)-1,2-diaminacyclohexane, 12, which was converted to the desired [H-3(2)]-(R,R)-1,2-diaminocyclohexaneoxalatoplatinum(II), [H-3(2)]-Oxaliplatin, 2.

  DOI：

  10.1002/(sici)1099-1344(199805)41:5<443::aid-jlcr100>3.0.co;2-w
• 作为产物：
  描述：

  rac-(trans)-cyclohex-4-ene-1,2-diamine dihydrochloride 在 sodium hydroxide 、 溶剂黄146 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 为溶剂， 生成 rac-di-tert-butyl (1,2-trans)-cyclohex-4-ene-1,2-diyldicarbamate
  参考文献：
  名称：

  Synthesis of [3H2]-(R,R)-1,2-diaminocyclohexaneoxalatoplatinum(II), [3H2]-Oxaliplatin

  摘要：

  A synthesis of [H-3(2)]-(R, R)-1,2-diaminocyclohexaneoxalatoplatinum(II), [H-3(2)-Oxaliplatin, 2, is described. rac-trans-4-Cyclohexene-1,2-dicarboxylic acid diethyl ester, 6, was converted to rac-trans-1,2-diaminocyclohex-4-ene, 7, by modification of known chemistry aimed at avoiding reported hazards. Resolution of the diamine, 7, with L-(+)-tartaric acid afforded the (R,R)-1,2-diaminocyclohex-4-ene, 8, which was converted to the (R,R)-1,2-bis(tert-butoxycarbamino)cyclohex-4-ene, 10, and tritiated to yield [H-3(2)-(R,R)-1,2-bis(tert-butoxycarbamino)cyclohexane, 11. Hydrolysis of 11 afforded [H-3(2)]-(R,R)-1,2-diaminacyclohexane, 12, which was converted to the desired [H-3(2)]-(R,R)-1,2-diaminocyclohexaneoxalatoplatinum(II), [H-3(2)]-Oxaliplatin, 2.

  DOI：

  10.1002/(sici)1099-1344(199805)41:5<443::aid-jlcr100>3.0.co;2-w

文献信息

• THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF
  申请人：GENENTECH, INC.

  公开号：US20190263786A1

  公开（公告）日：2019-08-29

  The invention provides a compound as described herein or a pharmaceutically acceptable salt thereof, and compositions containing such compounds and methods for using such compounds and compositions.

  本发明提供了一种如本文所述的化合物或其药用可接受的盐，以及含有该化合物的组合物和使用该化合物及组合物的方法。
• Chiral Auxiliary Induced Diastereoselective Synthesis of (<i>R</i>,<i>R</i>)-<i>N</i>,<i>N′</i>-Di(<i>tert</i>-butoxycarbonyl)cyclohex-4-ene-1,2-diamine
  作者：Davide Balestri、Stefano Grilli、Ciro Romano、Diego Savoia

  DOI：10.1002/ejoc.201403058

  日期：2014.12

  of the N-substituents by using an excess amount of boron trichloride, routine conversion to the di(N-tert-butoxycarbonyl) derivative, and final ring-closing metathesis by using Grubbs Ru catalyst. The sequence of the two latter steps could be inverted. Removal of the chiral auxiliaries with trifluoroacetic acid or hydrochloric acid gave less satisfactory results. Moreover, N,N′-dibenzoylocta-1,7-diene-4

  由乙二醛与(R)-1-缩合得到的二亚胺合成光学纯的N,N'-二(叔丁氧基羰基)-反式-环己-4-烯-1,2-二胺(4-甲氧基苯基)乙胺。合成顺序包括将烯丙基溴化锌高度非对映选择性加成到二亚胺中，得到 N,N'-二取代的八-1,7-二烯-4,5-二胺，然后使用过量的量去除 N-取代基三氯化硼，常规转化为二（N-叔丁氧基羰基）衍生物，并使用 Grubbs Ru 催化剂进行最终闭环复分解。后两个步骤的顺序可以颠倒。用三氟乙酸或盐酸去除手性助剂的结果不太令人满意。此外，类似地制备N,N'-dibenzoylocta-1,7-diene-4,5-diamine。
• 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF
  申请人：Novartis AG

  公开号：US20200016143A1

  公开（公告）日：2020-01-16

  The present disclosure provides a compound of Formula (I′): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R a , R b , R x , R 1 , R 2 , X 2 , and q are as defined herein, and methods of making and using same.

  本公开提供一种化合物Formula (I′)：或其药用盐、水合物、溶剂合物、前药、立体异构体或互变异构体，其中Ra、Rb、Rx、R1、R2、X2和q如本文所定义，并提供制备和使用该化合物的方法。
• DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM
  申请人：OHTA Toshiharu

  公开号：US20090281074A1

  公开（公告）日：2009-11-12

  Drug compositions containing a substituted diamine compound represented by formula (1): Q 1 -Q 2 -r-N(R 1 )-Q 3 -N(R 2 )  (1) wherein Q 3 represents the following group wherein Q 5 represents an alkylene group having 4 carbon atoms, R 3 represents a hydrogen atom, and R 4 represents a 3-6 membered heterocyclic group which may be substituted; are useful for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

  含有以下式子（1）所代表的取代二胺化合物的药物组合物： Q1-Q2-r-N（R1）-Q3-N（R2）  （1） 其中，Q3代表以下基团： 其中，Q5代表具有4个碳原子的烷基基团，R3代表氢原子，R4代表可取代的3-6环杂环基团； 该药物组合物对于预防和/或治疗脑梗死、脑栓塞、心肌梗死、心绞痛、肺梗死、肺栓塞、布尔格病、深静脉血栓形成、弥散性血管内凝血综合征、人工瓣膜或关节置换后的血栓形成、血管成形术后的血栓形成和再闭塞、全身性炎症反应综合征（SIRS）、多器官功能障碍综合征（MODS）、体外循环期间的血栓形成或采血时的血凝。
• Diamine derivatives
  申请人：Ohta Toshiharu

  公开号：US20060252837A1

  公开（公告）日：2006-11-09

  A compound represented by formula (1): Q 1 -Q 2 -T o -N(R 1 )-Q 3 -N(R 2 )-T 1 -Q 4 ( 1 ) [wherein R 1 and R 2 are hydrogen atoms or the like; Q 1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q 2 is a single bond or the like; Q 3 represents the following group: (wherein Q 5 is an alkylene group having 1 to 8 carbon atoms, or the like); and T 0 and T 1 are carbonyl groups or the like], a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

  化合物的化学式为(1): Q1-Q2-To-N(R1)-Q3-N(R2)-T1-Q4(1) [其中，R1和R2是氢原子或类似物; Q1是饱和或不饱和的、5-或6-成员的环烃基，可以被取代，或类似物; Q2是单键或类似物; Q3表示以下基团: (其中，Q5是具有1至8个碳原子的烷基或类似物); T0和T1是羰基基团或类似物]，其盐、溶剂化物或N-氧化物。该化合物可用作预防和/或治疗脑梗死、脑栓塞、心肌梗死、心绞痛、肺梗死、肺栓塞、布氏病、深静脉血栓形成、弥散性血管内凝血综合征、人工瓣膜或关节置换后的血栓形成、血管成形术后的血栓形成和再闭塞、全身性炎症反应综合征(SIRS)、多器官功能障碍综合征(MODS)、体外循环期间的血栓形成或采血时的血液凝结。